{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:29Z","timestamp":1791406829832,"version":"4.3.3"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jaci.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T05:21:00Z","timestamp":1471929660000},"page":"152-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":189,"title":["An IL-17\u2013dominant immune profile is shared across the major orphan forms of ichthyosis"],"prefix":"10.1016","volume":"139","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Renert-Yuval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suprun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-520X","authenticated-orcid":false,"given":"Hitokazu","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margeaux","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thy Nhat","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-1048","authenticated-orcid":false,"given":"Norma","family":"Kunjravia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-3656","authenticated-orcid":false,"given":"Rivka","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel D.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Choate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Su\u00e1rez-Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2016.07.019_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2009.11.020","article-title":"Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009","volume":"63","author":"Oji","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00128071-200304020-00002","article-title":"Ichthyosis: etiology, diagnosis, and management","volume":"4","author":"DiGiovanna","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib3","first-page":"349","article-title":"Ichthyoses: differential diagnosis and molecular genetics","volume":"16","author":"Oji","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/pd.2588","article-title":"Prevalence of steroid sulfatase deficiency in California according to race and ethnicity","volume":"30","author":"Craig","year":"2010","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jaci.2016.07.019_bib5","first-page":"109","article-title":"Nonsyndromic types of ichthyoses\u2014an update","volume":"12","author":"Traupe","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2016.07.019_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20082242","article-title":"Kallikrein\u00a05\u00a0induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome","volume":"206","author":"Briot","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2016.07.019_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/bjd.12219","article-title":"Ichthyosis vulgaris: the filaggrin mutation disease","volume":"168","author":"Thyssen","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.0309-2402.2003.02820.x","article-title":"Quality of life in adults with congenital ichthyosis","volume":"44","author":"Ganemo","year":"2003","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.jaci.2016.07.019_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2340\/00015555-1955","article-title":"Burden of inherited ichthyosis: a French national survey","volume":"95","author":"Dreyfus","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2016.07.019_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1525-1470.1992.tb00632.x","article-title":"Ichthyosis: mechanisms of disease","volume":"9","author":"Williams","year":"1992","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1194\/jlr.R800002-JLR200","article-title":"Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism","volume":"49","author":"Elias","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jaci.2016.07.019_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/exd.12366","article-title":"Increased cutaneous absorption reflects impaired barrier function of reconstructed\u00a0skin models mimicking keratinisation disorders","volume":"23","author":"Eckl","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaad.2013.05.017","article-title":"A\u00a0systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris","volume":"69","author":"Hernandez-Martin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2340\/00015555-0415","article-title":"Congenital ichthyosis: an overview of current and emerging therapies","volume":"88","author":"Vahlquist","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2016.07.019_bib15","first-page":"3","article-title":"Management of the ichthyoses","volume":"8","author":"Fleckman","year":"2003","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaci.2016.07.019_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1529-8019.2012.01527.x","article-title":"Systemic retinoids in the management of ichthyoses and related skin types","volume":"26","author":"Digiovanna","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2016.07.019_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1525-1470.2007.00331.x","article-title":"Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome","volume":"24","author":"Halverstam","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib18","first-page":"747","article-title":"Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome","volume":"137","author":"Allen","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng1493","article-title":"Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity","volume":"37","author":"Descargues","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1084\/jem.20131797","article-title":"Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome","volume":"211","author":"Furio","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2016.07.019_bib21","doi-asserted-by":"crossref","first-page":"e1005389","DOI":"10.1371\/journal.pgen.1005389","article-title":"KLK5 inactivation reverses cutaneous hallmarks of Netherton syndrome","volume":"11","author":"Furio","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib22","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1093\/hmg\/ddq145","article-title":"Interleukin-1 alpha blockade prevents hyperkeratosis in an in\u00a0vitro model of lamellar ichthyosis","volume":"19","author":"O'Shaughnessy","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.1523-1747.2000.00103.x","article-title":"Impaired cutaneous permeability barrier function, skin hydration, and sphingomyelinase activity in keratin 10 deficient mice","volume":"115","author":"Jensen","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib24","first-page":"5269","article-title":"Keratin 1 maintains skin integrity and participates in an inflammatory network in skin through interleukin-18","volume":"125","author":"Roth","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jaci.2016.07.019_bib25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bjd.13308","article-title":"A mouse organotypic tissue culture model for autosomal recessive congenital ichthyosis","volume":"171","author":"Rosenberger","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/jid.2012.250","article-title":"Aloxe3 knockout mice reveal a function of epidermal lipoxygenase-3 as hepoxilin synthase and its pivotal role in barrier formation","volume":"133","author":"Krieg","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib27","doi-asserted-by":"crossref","first-page":"36624","DOI":"10.1074\/jbc.M807377200","article-title":"ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters","volume":"283","author":"Zuo","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2016.07.019_bib28","doi-asserted-by":"crossref","first-page":"e1000192","DOI":"10.1371\/journal.pgen.1000192","article-title":"A\u00a0mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis","volume":"4","author":"Smyth","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib29","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/jid.2012.65","article-title":"Long-term faithful recapitulation of transglutaminase 1-deficient lamellar ichthyosis in a skin-humanized mouse model, and insights from proteomic studies","volume":"132","author":"Aufenvenne","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib30","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/jid.2010.233","article-title":"Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model","volume":"130","author":"Briot","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/hmg\/ddu459","article-title":"Fetal inhibition of inflammation improves disease phenotypes in harlequin ichthyosis","volume":"24","author":"Cottle","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.jid.5700284","article-title":"Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome","volume":"126","author":"Descargues","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib33","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/jid.2011.124","article-title":"Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin","volume":"131","author":"Fontao","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/08923973.2015.1115518","article-title":"A case of Netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels","volume":"38","author":"Yalcin","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.jaci.2016.07.019_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2340\/00015555-0573","article-title":"Expression of retinoid-regulated genes in lamellar ichthyosis vs. healthy control epidermis: changes after oral treatment with liarozole","volume":"89","author":"Pavez Lorie","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2016.07.019_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jamadermatol.2015.5827","article-title":"Intrafamily and interfamilial phenotype variation and immature immunity in patients with Netherton syndrome and Finnish SPINK5 founder mutation","volume":"152","author":"Hannula-Jouppi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaad.2004.11.033","article-title":"Comel-Netherton syndrome in brothers and expression of cytokeratins","volume":"52","author":"de Oliveira","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/1346-8138.12410","article-title":"Upregulation of interleukin-33 in the epidermis of two Japanese patients with Netherton syndrome","volume":"41","author":"Konishi","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000051607","article-title":"Clinico-immunological heterogeneity in Comel-Netherton syndrome","volume":"202","author":"Van Gysel","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2016.07.019_bib40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Comel-Netherton syndrome defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib41","first-page":"744","article-title":"Caspase-1 activity of stratum corneum and serum interleukin-18 level are increased in patients with Netherton syndrome","volume":"159","author":"Hosomi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib42","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/1346-8138.12209","article-title":"Case of Netherton syndrome with an elevated serum thymus and activation-regulated chemokine level","volume":"40","author":"Akagi","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jid.2011.366","article-title":"Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations","volume":"132","author":"Lacroix","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib47","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/jid.2014.268","article-title":"IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood","volume":"134","author":"Wang","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1525-1470.2010.01114.x","article-title":"Reliable methods to evaluate the clinical severity of ichthyosis","volume":"27","author":"Kamalpour","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaci.2016.07.019_bib50","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib52","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/jid.2010.166","article-title":"Effective narrow-band UVB radiation therapy suppresses the IL-23\/IL-17 axis in normalized psoriasis plaques","volume":"130","author":"Johnson-Huang","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and\u00a0biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib54","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaci.2013.04.043","article-title":"Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases","volume":"132","author":"Dhingra","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2014.10.037","article-title":"Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection","volume":"135","author":"Esaki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib56","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2015.08.027","article-title":"Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis","volume":"137","author":"Czarnowicki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1468-3083.2002.00478.x","article-title":"Collodion baby: what's new","volume":"16","author":"Taieb","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2016.07.019_bib59","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1468-3083.2002.00477.x","article-title":"Collodion baby: a follow-up study of 17 cases","volume":"16","author":"Van Gysel","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2016.07.019_bib60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng0395-279","article-title":"Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis","volume":"9","author":"Russell","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib61","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/jid.2008.409","article-title":"Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B","volume":"129","author":"Eckl","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib62","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/jid.2009.57","article-title":"Autosomal recessive congenital ichthyosis","volume":"129","author":"Fischer","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/75977","article-title":"Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome","volume":"25","author":"Chavanas","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib64","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.jid.5700288","article-title":"Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome","volume":"126","author":"Hachem","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib66","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/jcm4050858","article-title":"Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics","volume":"4","author":"Mansouri","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2016.07.019_bib67","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib68","doi-asserted-by":"crossref","first-page":"e75355","DOI":"10.1371\/journal.pone.0075355","article-title":"Distinguishing ichthyoses by protein profiling","volume":"8","author":"Rice","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2016.07.019_bib69","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib70","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1091\/mbc.e07-02-0124","article-title":"LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction","volume":"18","author":"Deraison","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jaci.2016.07.019_bib71","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jaci.2009.09.031","article-title":"Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis","volume":"124","author":"Guttman-Yassky","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib72","doi-asserted-by":"crossref","first-page":"e10247","DOI":"10.1371\/journal.pone.0010247","article-title":"Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA)","volume":"5","author":"Suarez-Farinas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2016.07.019_bib73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib74","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/jid.2014.308","article-title":"IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis","volume":"134","author":"Witte","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib75","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.4049\/jimmunol.173.11.6712","article-title":"IL-19 induced Th2 cytokines and was up-regulated in asthma patients","volume":"173","author":"Liao","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib76","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/ndt\/gfm179","article-title":"Expression of IL-19 correlates with Th2 cytokines in uraemic patients","volume":"22","author":"Hsing","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaci.2016.07.019_bib77","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.intimp.2004.01.005","article-title":"Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses","volume":"4","author":"Gallagher","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2016.07.019_bib78","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2008.04.016","article-title":"Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4\/IL-13: important implications in asthma","volume":"121","author":"Huang","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib79","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Cedeno-Laurent","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib82","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/hmg\/ddi030","article-title":"Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome","volume":"14","author":"Hewett","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2016.07.019_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14570","article-title":"Epidermal filaggrin deficiency mediates increased systemic Th17 immune response","author":"Bonefeld","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib84","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.07.019_bib85","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14728222.2014.889686","article-title":"Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?","volume":"18","author":"Chiricozzi","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaci.2016.07.019_bib86","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib87","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaci.2016.07.019_bib88","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaci.2016.07.019_bib89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.07.019_bib90","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1586\/1744666X.2015.1095092","article-title":"Secukinumab (AIN457) for the treatment of psoriasis","volume":"11","author":"Lopez-Ferrer","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib91","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.07.019_bib92","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2016.07.019_bib93","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib95","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.07.019_bib96","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib97","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib98","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D'Erme","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib99","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","article-title":"Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis","volume":"181","author":"Guttman-Yassky","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib100","doi-asserted-by":"crossref","first-page":"e90284","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2016.07.019_bib101","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2014.07.061","article-title":"Peeling off the genetics of atopic dermatitis-like congenital disorders","volume":"134","author":"Samuelov","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib102","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF00493471","article-title":"Flow cytometric quantification of human epidermal cells expressing keratin 16 in\u00a0vivo after standardized trauma","volume":"282","author":"de Mare","year":"1990","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2016.07.019_bib103","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4049\/jimmunol.0901829","article-title":"IL-24 transgenic mice: in\u00a0vivo evidence of overlapping functions\u00a0for IL-20, IL-22, and IL-24 in the epidermis","volume":"184","author":"He","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib104","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.jid.5700310","article-title":"Prominent production of IL-20 by CD68+\/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects","volume":"126","author":"Wang","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib105","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22\u00a0inhibits epidermal differentiation and induces proinflammatory gene\u00a0expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib106","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib107","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1038\/jid.2014.205","article-title":"Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis","volume":"134","author":"Ye","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/1346-8138.12393","article-title":"Defective barrier function accompanied by structural changes of psoriatic stratum corneum","volume":"41","author":"Takahashi","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2230.2005.01818.x","article-title":"Structural, enzymatic and molecular studies in a series of nonbullous congenital ichthyosiform erythroderma patients","volume":"30","author":"Kawashima","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib110","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1159\/000362789","article-title":"The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function","volume":"6","author":"Akiyama","year":"2014","journal-title":"J Innate Immun"},{"key":"10.1016\/j.jaci.2016.07.019_bib111","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/jid.2014.143","article-title":"Host defense (Antimicrobial) peptide, human beta-defensin-3, improves the function of the epithelial tight-junction barrier in human keratinocytes","volume":"134","author":"Kiatsurayanon","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib112","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaci.2016.07.019_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaci.2009.11.027","article-title":"Recent insights into atopic dermatitis and implications for management of infectious complications","volume":"125","author":"Boguniewicz","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib114","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/pde.12769","article-title":"Recurrent coxsackievirus infection in a patient with lamellar ichthyosis","volume":"33","author":"Damsky","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib115","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/pde.12728","article-title":"Congenital ichthyosiform erythroderma superimposed with chronic dermatophytosis: a report of three siblings","volume":"33","author":"Vyas","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib116","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1590\/abd1806-4841.20131854","article-title":"Ichthyosis associated with widespread tinea corporis: report of three cases","volume":"88","author":"Freitas","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib117","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-trem safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib118","unstructured":"Cosentyx (secukinumab) prescribing information. Available at: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/cosentyx.pdf. Accessed June 17, 2016."},{"key":"10.1016\/j.jaci.2016.07.019_bib119","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0269881110367727","article-title":"TC-1734 (AZD3480) AAMI Clinical Study\u00a0Group (USA). A\u00a0randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment","volume":"25","author":"Dunbar","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jaci.2016.07.019_bib120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clim.2011.03.018","article-title":"Age-associated alteration in naive and memory Th17 cell response in humans","volume":"140","author":"Lee","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib121","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a\u00a0randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.07.019_bib122","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1067\/mjd.2002.120472","article-title":"Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab","volume":"46","author":"Schopf","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2016.07.019_bib123","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib124","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene\u00a0expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2016.07.019_bib125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/13543784.2013.806483","article-title":"IL-17 targeted therapies for psoriasis","volume":"22","author":"Chiricozzi","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaci.2016.07.019_bib126","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916308065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674916308065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:02:17Z","timestamp":1758790937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674916308065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0091674916308065"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2016.07.019","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An IL-17\u2013dominant immune profile is shared across the major orphan forms of ichthyosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}